Literature DB >> 15085081

Sera from patients with collapsing focal segmental glomerulosclerosis increase albumin permeability of isolated glomeruli.

Ellen T McCarthy1, Mukut Sharma, Ram Sharma, Ronald J Falk, J Charles Jennette.   

Abstract

The collapsing variant of focal segment glomerulosclerosis (FSGS) is characterized by heavy proteinuria and rapid progression to renal failure. Its cause is not known. We have characterized a substance in the circulation of patients with classic FSGS that increases in vitro permeability of glomeruli to albumin (P(alb)) and causes proteinuria when injected into rats. Inclusion of normal serum prevents the increase in P(alb) caused by this FSGS factor. We investigated the effect of sera from patients with collapsing FSGS on P(alb), as well as the effect of inclusion of normal serum. Isolated glomeruli were incubated with serum from each of 11 patients with collapsing FSGS (1:50 dilution) or with patient serum and an equal volume of pooled normal serum. P(alb) was determined on the basis of changes in glomerular volume in response to an oncotic gradient. Sera from 10 of the 11 patients with collapsing FSGS increased P(alb) of isolated glomeruli to a value of 0.5 or greater. In each of the 5 cases tested, inclusion of normal serum abolished the increase in P(alb). Sera of patients with collapsing FSGS increased glomerular P(alb). Our finding that the increase in P(alb) is abolished by normal serum suggests that the substance and its mechanism of action are similar or identical to the FSGS factor we have isolated from the plasma of patients with recurrent FSGS. The presence of a circulating factor in collapsing FSGS has implications for prognosis and treatment in primary and recurrent collapsing FSGS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15085081     DOI: 10.1016/j.lab.2004.01.007

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  8 in total

1.  TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation.

Authors:  Martin Bitzan; Sima Babayeva; Anil Vasudevan; Paul Goodyer; Elena Torban
Journal:  Pediatr Nephrol       Date:  2012-04-27       Impact factor: 3.714

Review 2.  Glomerular diseases: FSGS.

Authors:  Bhadran Bose; Daniel Cattran
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

Review 3.  Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients.

Authors:  Jeremy Kiffel; Yael Rahimzada; Howard Trachtman
Journal:  Adv Chronic Kidney Dis       Date:  2011-09       Impact factor: 3.620

4.  Circulating suPAR in two cohorts of primary FSGS.

Authors:  Changli Wei; Howard Trachtman; Jing Li; Chuanhui Dong; Aaron L Friedman; Jennifer J Gassman; June L McMahan; Milena Radeva; Karsten M Heil; Agnes Trautmann; Ali Anarat; Sevinc Emre; Gian M Ghiggeri; Fatih Ozaltin; Dieter Haffner; Debbie S Gipson; Frederick Kaskel; Dagmar-Christiane Fischer; Franz Schaefer; Jochen Reiser
Journal:  J Am Soc Nephrol       Date:  2012-11-08       Impact factor: 10.121

5.  Recurrent focal segmental glomerulosclerosis: a discrete clinical entity.

Authors:  Elena Torban; Martin Bitzan; Paul Goodyer
Journal:  Int J Nephrol       Date:  2012-01-11

6.  Free radical scavenging decreases endothelin-1 excretion and glomerular albumin permeability during type 1 diabetes.

Authors:  Mohamed A Saleh; Carmen De Miguel; David I Stevens; Pamela K Carmines; David M Pollock; Jennifer S Pollock
Journal:  Physiol Rep       Date:  2016-12

Review 7.  Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor.

Authors:  Virginia J Savin; Mukut Sharma; Jianping Zhou; David Genochi; Ram Sharma; Tarak Srivastava; Amna Ilahe; Pooja Budhiraja; Aditi Gupta; Ellen T McCarthy
Journal:  Biomed Res Int       Date:  2017-08-10       Impact factor: 3.411

Review 8.  Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  Virginia J Savin; Ellen T McCarthy; Mukut Sharma
Journal:  Kidney Res Clin Pract       Date:  2012-10-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.